Given our finding that CRP reprograms myeloid cells we therefore think that cancer might represent a promising opportunity for beneficial CRP lowering, i.e. reducing blood CRP levels should result in fewer MDSCs and a less immunosuppressive tumor microenvironment, thereby potentiating anti-tumor T cell responses. The gene discussed is CRP; the disease is cancer.